Aquestive Therapeutics Q3 2026 Earnings Date & Estimates

Aquestive Therapeutics (NASDAQ:AQST) is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products that use its proprietary PharmFilm oral film technology. The company’s films are designed to deliver medicines through the mouth, potentially offering alternatives to tablets, capsules, injections, or other conventional dosage forms.

Aquestive’s marketed products include Libervant (diazepam buccal film), an FDA-approved treatment for the acute, intermittent, and stereotypic episodes of frequent seizure activity associated with epilepsy, and Exservan (riluzole oral film), an FDA-approved treatment for amyotrophic lateral sclerosis. The company also markets Sympazan (clobazam oral film) for certain patients with Lennox-Gastaut syndrome.

In addition to its commercial products, Aquestive is advancing a pipeline of oral film medicines and product candidates intended to address conditions in areas such as neurology, emergency medicine, and other specialty-care markets. The company serves primarily the U.S. market and has pursued partnerships and licensing opportunities to expand the use of its drug-delivery technology.